Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases

by B2i | Oct 5, 2023 | Press Releases

JUPITER, Fla., Oct. 05, 2023 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...

Dyadic to Present at Industry and Investor Events in October

by B2i | Sep 29, 2023 | Press Releases

JUPITER, Fla., Sept. 29, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

by B2i | Sep 26, 2023 | Press Releases

JUPITER, Fla. and PARIS, Sept. 26, 2023 — Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (“bYoRNA”) today announced that they entered into a development and commercialization agreement to work on disruptive...

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

by B2i | Sep 19, 2023 | Press Releases

Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. 19, 2023 — Dyadic International, Inc....

Dyadic to Present at BioProcess International

by B2i | Sep 12, 2023 | Press Releases

JUPITER, Fla., Sept. 12, 2023 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...